RÉSUMÉ
The present guideline is focused on quality assurance of somatostatin receptor PET/CT (SSTR-PET/CT) in oncology patients. The document has been developed by a multidisciplinary board of specialists providing consensus of definitions, prerequisites, methodology, operating procedures, assessment, and standardized reporting. In particular, imaging procedures for the two most commonly used radioligands of human SSTR, i. e. 68Ga-DOTATOC and 68Ga-DOTATATE are presented. Overall, SSTR-PET/CT requires close interdisciplinary communication and cooperation of referring and executing medical disciplines, taking into account existing guidelines and recommendations of the European and German medical societies, including the European Association of Nuclear Medicine (EANM), German Society for Endocrinology (DGE), German Society for Nuclear Medicine (DGN) and German Society for Radiology (DRG).
Sujet(s)
Tomographie par émission de positons couplée à la tomodensitométrie , Guides de bonnes pratiques cliniques comme sujet , Récepteur somatostatine/métabolisme , Humains , Tumeurs/imagerie diagnostique , Tumeurs/métabolisme , RadiopharmaceutiquesSujet(s)
Glutamate carboxypeptidase II/antagonistes et inhibiteurs , Tumeurs prostatiques résistantes à la castration/radiothérapie , Radiopharmaceutiques/usage thérapeutique , Antigènes de surface , Essais cliniques comme sujet , Docetaxel , Europe , Humains , Ligands , Lutétium/effets indésirables , Lutétium/usage thérapeutique , Mâle , Oligopeptides/effets indésirables , Oligopeptides/pharmacologie , Oligopeptides/usage thérapeutique , Tumeurs prostatiques résistantes à la castration/traitement médicamenteux , Radiopharmaceutiques/effets indésirables , Radiopharmaceutiques/pharmacologie , Taxoïdes/effets indésirables , Taxoïdes/usage thérapeutiqueRÉSUMÉ
Neuroendocrine neoplasms (NEN) of the breast are specific tumor entities. According to the literature up to 5% of breast neoplasms are malignant epithelial neoplasms of the breast. They are defined by a neuroendocrine (NE) architecture and cytology combined with an expression of the neuroendocrine vesicle markers chromogranin A and/or synaptophysin. The diagnosis is supplemented by the receptor status and the proliferative activity. According to the World Health Organization (WHO) classification of 2012 the following groups of NEN are distinguished: (1) invasive breast carcinoma with NE differentiation, (2) well-differentiated neuroendocrine tumor (NET) and (3) poorly differentiated small cell carcinoma (NEC). This review article focuses on (1) the definition and basic principles of diagnostics, (2) the history, nomenclature and WHO classification from 2003 and 2012, (3) the frequency of breast NEN, (4) the hereditary background and functional activity, (5) the expression of receptors and (6) the possible clinical implications. In addition, the first results of a retrospective single center study (n = 465 patients with breast cancer over a time period of 4 years) on the frequency of NEN of the breast at the Breast Center of the University Hospital Düsseldorf are presented. In this study a frequency of 4.5% of NEN was found based on a diagnostic cut-off of > 50% Chromogranin A and/or synaptophysin positive tumor cells.
Sujet(s)
Tumeurs du sein/anatomopathologie , Tumeurs neuroendocrines/anatomopathologie , Marqueurs biologiques tumoraux/analyse , Région mammaire/anatomopathologie , Prolifération cellulaire , Chromogranine A/analyse , Femelle , Humains , Invasion tumorale , Pronostic , Synaptophysine/analyseRÉSUMÉ
AIM: Clinical differentiation of psoriatic arthritis (PsA) and rheumatoid arthritis (rA) based on the pattern of joint involvement can be difficult; the frequent form of PsA with polyarthritis of the peripheral joints may sometime resemble rA. We investigated a metabolic joint asymmetry score (MJAS), reflecting the overall asymmetric joint involvement on conventional bone scintigraphy, for differentiating PsA from rA in patients presenting with peripheral polyarthritis. PATIENTS, METHODS: 106 patients (n = 61, PsA; n = 45, rA) with peripheral polyarthritis (≥ 5 joints) as well as 26 control subjects with no history of chronic joint disorders were analyzed. The intensity of articular 99mTc-MDP uptake in 40 peripheral joint pairs was scored regarding the bilateral difference of each joint based on a scale of 0-2 (no significant, moderate, and marked asymmetry, respectively). The patient's MJAS was defined as the sum of uptake difference scores of all joint pairs. The association of MJAS with the underlying condition (Psoriasis criteria, Revised Criteria of the ACR) was examined. RESULTS: 5280 peripheral joint pairs were investigated. There was no significant difference in the total number of involved joints in PsA 15.0 ± 8.2 versus rA 17.5 ± 8.8 patients (p = 0.132), but significantly less involvement in the control group (6.7 ± 5.0, p < 0.001). MJAS was markedly higher in PsA (17.0 ± 9.6) than in rA (4.8 ± 3.9, p < 0.001), and correlated with the total number of involved joints in PsA (r = 0.516, p < 0.001), but not in rA (r = 0.078, p = 0.380). The MJAS disparity between PsA and rA persisted after exclusion of the DIP joints (14.4 ± 7.7 vs. 4.4 ± 3.3; p<0.001). CONCLUSIONS: The new reproducible semi-quantification method for the asymmetry of metabolic joint involvement permits differentiation of psoriatic from rheumatoid peripheral arthritis with MJAS being markedly higher in patients with PsA as compared to rA patients. The score may offer an effective complementary tool for characterizing patients with peripheral polyarthritis.
Sujet(s)
Arthrite psoriasique/imagerie diagnostique , Arthrite psoriasique/métabolisme , Polyarthrite rhumatoïde/imagerie diagnostique , Polyarthrite rhumatoïde/métabolisme , Interprétation d'images assistée par ordinateur/méthodes , Médronate de technétium (99mTc)/pharmacocinétique , Adulte , Sujet âgé , Os et tissu osseux/imagerie diagnostique , Os et tissu osseux/métabolisme , Simulation numérique , Diagnostic différentiel , Femelle , Humains , Amélioration d'image/méthodes , Mâle , Adulte d'âge moyen , Modèles biologiques , Scintigraphie , Radiopharmaceutiques/pharmacocinétique , Reproductibilité des résultats , Sensibilité et spécificité , LogicielRÉSUMÉ
This document describes the guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the official AWMF Guideline Registry. These recommendations are a prerequisite for the quality management in the treatment of patients with somatostatin receptor expressing tumours using PRRT. They are aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRT and to deliver the treatment in a safe and effective manner. The recommendations are based on an interdisciplinary consensus. The document contains background information and definitions and covers the rationale, indications and contraindications for PRRT. Essential topics are the requirements for institutions performing the therapy, e. g. presence of an expert for medical physics, intense cooperation with all colleagues involved in the treatment of a patient, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with the involved medical disciplines. Generally, the decision for PRRT should be undertaken within the framework of a multi-disciplinary tumour board.
Sujet(s)
Tumeurs/métabolisme , Tumeurs/radiothérapie , Peptides/pharmacocinétique , Radio-oncologie/normes , Radiopharmaceutiques/usage thérapeutique , Récepteur somatostatine/métabolisme , Allemagne , Humains , Guides de bonnes pratiques cliniques comme sujet , Radiopharmaceutiques/pharmacocinétiqueRÉSUMÉ
UNLABELLED: After ankle and knee, the elbow is the most frequent joint affected by haemophilic arthropathy. The objective of this retrospective single centre study is to evaluate the results of treatment of elbow arthropathy after failed conservative therapy. PATIENTS, METHODS: In 21 consecutive patients, 11 radiosynoviortheses (RSO), four arthroscopic and six open synovectomies were performed, among them four with additional resection of the radial head. The mean duration of follow-up was 4.8 (RSO) and 5.3 years (surgery), respectively. Pain status (visual analogue scale, VAS), bleeding frequency, range of motion (ROM) as well as patient satisfaction were evaluated. RESULTS: Both, RSO and surgical synovectomy, achieved a significant reduction of pain and bleeding frequency (p < 0.05). Surgical synovectomies were associated with a marked yet not statistically significant increase of postoperative ROM. Radial head resection improved forearm rotation in all cases. No complications occurred. 20 out of 21 patients were satisfied or highly satisfied with the result of the treatment and would undergo the respective procedure again. CONCLUSION: Due to the effectiveness and safety RSO is considered to be the primary treatment option in haemophilic arthropathy of the elbow after failed conservative therapy. Arthroscopic synovectomy should be considered if RSO shows inadequate effect or in the presence of contraindications. Open synovectomy with resection of the radial head yields good results in the case of advanced arthropathy with radial head impingement.
Sujet(s)
Arthroscopie/méthodes , Articulation du coude/chirurgie , Hémarthrose/diagnostic , Hémarthrose/thérapie , Radiothérapie conformationnelle/méthodes , Adolescent , Adulte , Association thérapeutique/méthodes , Articulation du coude/effets des radiations , Femelle , Humains , Mâle , Adulte d'âge moyen , Sécurité des patients , Satisfaction des patients , Études rétrospectives , Synovectomie , Échec thérapeutique , Résultat thérapeutique , Jeune adulteRÉSUMÉ
AIM: This retrospective study aims to evaluate the predictive value of FDG PET/CT in patients with unresectable hepatocellular carcinoma (HCC) undergoing radioembolization with yttrium-90 labeled microspheres (RE). PATIENTS, METHODS: The study cohort comprised 33 patients who were treated with RE at our institution and underwent FDG PET/CT at baseline and four weeks after radioembolization. According to the baseline FDG metabolic status of the HCC lesions, patients were divided into two groups: FDG-negative (n = 12) and FDG-positive (n = 21) HCC. FDG-positive patients were further divided into early metabolic responders and non-responders according to the relative change in SUVmax of the treated lesions. Survival analyses were performed with the Kaplan-Meier method (log-rank test, p < 0.05). Multivariate analysis was performed to assess the influence of prognostic factors on overall survival (OS). RESULTS: FDG-negative patients had a significantly longer OS (13 months, 95%CI 7-19) than FDG-positive patients (9 months, 95%CI 7-11; p = 0.010). Among FDG-positive patients, metabolic responders survived significantly longer than metabolic non-responders (10 months, 95%CI 8-12 vs. 5 months, 95%CI 4-6; p = 0.003). From the other baseline factors (including performance status, hepatic tumour burden, presence of extra-hepatic disease, administered activity) only the BCLC stage had a significant impact on OS (p = 0.028). CONCLUSION: Pre- and post-therapeutic FDG PET independently predicts overall survival in patients with HCC undergoing radioembolization. Interestingly, early metabolic response seems to be assessable as early as four weeks post-treatment.
Sujet(s)
Curiethérapie , Carcinome hépatocellulaire/imagerie diagnostique , Carcinome hépatocellulaire/radiothérapie , Fluorodésoxyglucose F18 , Tumeurs du foie/imagerie diagnostique , Tumeurs du foie/radiothérapie , Tomographie par émission de positons/méthodes , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Microsphères , Adulte d'âge moyen , Pronostic , Radiopharmaceutiques/usage thérapeutique , Reproductibilité des résultats , Études rétrospectives , Sensibilité et spécificité , Taux de survie , Radio-isotopes de l'yttrium/usage thérapeutiqueRÉSUMÉ
AIM: Highly advanced metastatic bone disease with extensive osseous infiltration of neuroendocrine tumours (NET) may preclude patients from treatment with peptide receptor radionuclide therapy (PRRT) in concern about haematotoxicity. This study aims to assess the safety and efficacy of PRRT with 177Lu-octreotate in a patient cohort with this condition. PATIENTS, METHODS: 41 PRRT courses were performed in 11 patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET) and florid bone metastases (severely advanced widespread metastatic bone disease). A mean activity of 6.95 GBq 177Lu-octreotate was administered per treatment cycle, aimed at four courses with standard intervals of 3 months. Haematological parameters were determined prior to each treatment course, in 2-4 weeks intervals between the courses, 8-12 weeks after the last course of PRRT and in 3 monthly intervals thereafter. Toxicity was recorded using Common Terminology Criteria for Adverse Events v3.0. Restaging was performed 3 months after termination of PRRT with CT/MRI and functional imaging (modified MDA criteria). RESULTS: Significant (grade III-IV), reversible haematotoxicity occurred in 4 (35%) patients and after 10 (24%) administrations. It either resolved spontaneously (1 patient) or was controlled by supportive measures (3 patients), such as blood transfusions (3 patients) or deferral of the subsequent therapy cycle (1 patient). Patients returned to baseline blood values within up to 23 months after termination of PRRT. The observed treatment response of bone metastases consisted of a partial response in 2, a minor response in 1, stable disease in 7, and progressive disease in 1 patient. Of the 4 patients with metastatic bone pain, 1 experienced complete and 3 partial resolution of symptoms within 3-10 weeks after commencement of PRRT. CONCLUSION: These preliminary data indicate that PRRT with 177Lu-octreotate can be safely applied even in florid bone metastases with extensive, severely advanced osseous replacement. The higher myelosuppression rate was not associated with serious complications and should not preclude patients from being treated and potentially experiencing remarkable treatment efficacy despite the very advanced stage.
Sujet(s)
Maladies de la moelle osseuse/étiologie , Tumeurs osseuses/radiothérapie , Tumeurs osseuses/secondaire , Tumeurs neuroendocrines/radiothérapie , Tumeurs neuroendocrines/secondaire , Octréotide/analogues et dérivés , Lésions radiques/étiologie , Adulte , Sujet âgé , Maladies de la moelle osseuse/imagerie diagnostique , Tumeurs osseuses/métabolisme , Études de cohortes , Femelle , Humains , Mâle , Adulte d'âge moyen , Tumeurs neuroendocrines/métabolisme , Octréotide/effets indésirables , Octréotide/pharmacocinétique , Octréotide/usage thérapeutique , Projets pilotes , Lésions radiques/imagerie diagnostique , Scintigraphie , Radiopharmaceutiques/effets indésirables , Radiopharmaceutiques/pharmacocinétique , Radiopharmaceutiques/usage thérapeutique , Récepteurs peptidiques/métabolisme , Études rétrospectives , Résultat thérapeutiqueRÉSUMÉ
Neuroendocrine neoplasms (NEN) of the distal jejunum and ileum derive from serotonin-producing enterochromaffin (EC) cells. Due to their low proliferation rate and their infiltrative growth, they are often discovered at an advanced disease stage when metastasis has already occurred. The biology of these tumours is different from other NEN of the digestive tract. In order to standardise and improve diagnosis and therapy, the guidelines for the diagnosis and clinical management of jejuno-ileal NEN as well as for the management of patients with liver and other distant metastases from NEN were revised by the European Neuroendocrine Tumour Society (ENETS) in 2012. This review focuses on aspects relevant for surgical pathology.
Sujet(s)
Tumeurs de l'iléon/anatomopathologie , Tumeurs du jéjunum/anatomopathologie , Tumeurs neuroendocrines/anatomopathologie , Prolifération cellulaire , Diagnostic différentiel , Évolution de la maladie , Cellules entérochromaffines/anatomopathologie , Humains , Tumeurs de l'iléon/chirurgie , Iléum/anatomopathologie , Iléum/chirurgie , Tumeurs du jéjunum/chirurgie , Jéjunum/anatomopathologie , Jéjunum/chirurgie , Tumeurs neuroendocrines/chirurgie , Guides de bonnes pratiques cliniques comme sujet , Récepteur somatostatine/analyseRÉSUMÉ
No disponible
Sujet(s)
Humains , Mâle , Adulte d'âge moyen , Tumeurs de la prostate , Métastase tumorale , Tumeurs du foie/complications , Tumeurs du foie , Rhénium , Tomographie d'émission monophotonique cardiaque synchronisée à l'ECG , Prostate/anatomopathologie , Prostate , Hémopathies et maladies lymphatiques/complications , Hémopathies et maladies lymphatiques , Maladies lymphatiques/complications , Maladies lymphatiquesRÉSUMÉ
UNLABELLED: This study investigated the efficacy of 131iodine-labeled lipiodol (131I-lipiodol) as a palliative therapy, evaluated overall survival (OS) across Barcelona Clinic Liver Cancer (BCLC) stages, and determined the main prognostic factors influencing OS in patients with hepatocellular carcinoma (HCC). PATIENTS, METHODS: We retrospectively analyzed 57 (44 men; mean age, 65.7 years; mean activity per session, 1.6 GBq; mean cumulative activity in patients with >1 sessions, 3.9 GBq) HCC patients who underwent 131I-lipiodol therapy. A majority of patients exhibited Child-Pugh class B (53.6%) disease and a good Eastern Cooperative Oncology Group performance status (0-1; 72%). Multinodular disease was observed in 87.7% patients, bilobar disease in 73%, and portal vein occlusion (PVO) in 54%. Furthermore, 21.1% patients were staged as BCLC B and 59.6 % as BCLC C. All patients were followed until death. RESULTS: The median OS was 6.4 months, which varied significantly with disease stage (median OS for BCLC A, B, C, and D was 29.4, 12.0, 4.6, and 2.7 months, respectively; p = 0.009); Child-Pugh score and class; presence of ascites, PVO, or extrahepatic disease; largest lesion size; favourable treatment response; international normalized ratio, baseline albumin and alpha-fetoprotein levels. Patients with a Child-Pugh A liver disease had a longer OS. CONCLUSION: Currently, different treatment modalities for HCC include radioembolization, transarterial chemoembolization, and systemic therapy with sorafenib; however, 131I-lipiodol therapy remains a feasible alternative for patients without a favourable response to other therapies, particularly for patients with Child-Pugh A liver cirrhosis.
Sujet(s)
Carcinome hépatocellulaire/radiothérapie , Huile éthiodée/usage thérapeutique , Tumeurs du foie/radiothérapie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Carcinome hépatocellulaire/imagerie diagnostique , Chimioradiothérapie , Femelle , Études de suivi , Humains , Tumeurs du foie/imagerie diagnostique , Études longitudinales , Mâle , Adulte d'âge moyen , Scintigraphie , Radiopharmaceutiques/usage thérapeutique , Études rétrospectives , Taux de survie , Résultat thérapeutiqueSujet(s)
Adénocarcinome/secondaire , Acide étidronique/usage thérapeutique , Tumeurs du foie/secondaire , Composés organométalliques/usage thérapeutique , Tumeurs de la prostate/anatomopathologie , Adénocarcinome/imagerie diagnostique , Adénocarcinome/radiothérapie , Sujet âgé , Tumeurs osseuses/radiothérapie , Tumeurs osseuses/secondaire , Acide étidronique/pharmacocinétique , Tube digestif/imagerie diagnostique , Humains , Tumeurs du foie/imagerie diagnostique , Métastase lymphatique , Mâle , Imagerie multimodale , Composés organométalliques/pharmacocinétique , Radiopharmaceutiques/pharmacocinétique , Distribution tissulaire , Tomographie par émission monophotonique , TomodensitométrieRÉSUMÉ
PURPOSE: This study was designed to assess the additional value of SPECT/CT of the trunk used in conjunction with conventional nuclear imaging and its effects on patient management in a large patient series. METHODS: In 353 patients, whole-body scintigraphy (WBS), SPECT, and SPECT/CT were prospectively performed for staging and restaging. SPECT/CT of the trunk was performed in all patients. In the 308 evaluable patients (211 with breast cancer, 97 with prostate cancer), clinical follow-up was used as the gold standard. Bone metastases were confirmed in 72 patients and excluded in 236. Multistep analyses per lesion and per patient were performed. Clinical relevance was expressed in terms of downstaging and upstaging rates on a per-patient basis. RESULTS: In the total patient group, sensitivities, specificities, and negative and positive predictive values on a per-patient basis were 93 %, 78 %, 95 % and 59 % for WBS, 94 %, 71 %, 97 % and 53 % for SPECT, and 97 %, 94 %, 97 % and 88 % for SPECT/CT, respectively. In all subgroups, specificity and positive predictive value were significantly (p<0.01) better with SPECT/CT. Downstaging of metastatic disease in the total, breast cancer and prostate cancer groups using SPECT/CT was possible in 32.1 %, 33.8 % and 29.5 % of patients, respectively. Upstaging in previously negative patients by additional SPECT/CT was observed in three breast cancer patients (2.1 %). Further diagnostic imaging procedures for unclear scintigraphic findings were necessary in only 2.5 % of patients. SPECT/CT improved diagnostic accuracy for defining the extent of multifocal metastatic disease in 34.6 % of these patients. CONCLUSIONS: SPECT/CT significantly improved the specificity and positive predictive value of bone scintigraphy in cancer patients. In breast cancer patients, we found a slight increase in sensitivity. SPECT/CT had a significant effect on clinical management because of correct downstaging and upstaging, better definition of the extent of metastases, and a reduction in further diagnostic procedures.
Sujet(s)
Tumeurs osseuses/secondaire , Os et tissu osseux/imagerie diagnostique , Imagerie multimodale , Tomographie par émission monophotonique , Tomodensitométrie , Imagerie du corps entier , Tumeurs osseuses/imagerie diagnostique , Femelle , Humains , Mâle , Adulte d'âge moyen , Courbe ROCRÉSUMÉ
UNLABELLED: The actual number of resin microspheres is approximately 30-60 times higher than glass microspheres per 3 GBq vial. Thus, radioembolization (RE) with resin microspheres exerts an embolization effect besides the radiation effect. This embolization effect can occasionally cause early back flow of the microspheres before application of the entire calculated dose. To avoid these adverse side effects, RE has to be terminated at an earlier time point. Measurement of the residual activity in the delivery box, which includes the v-vial, tube and catheter, to calculate the achieved target dose is often challenging. The aim of the current study was to establish a post-RE measurement method comparable to the glass microspheres method without unnecessary radiation exposure to the staff and risk of contamination. METHODS: Two different measurements were performed. First, total radioactivity in the shipping vial was measured in an ion chamber and then it was put in the delivery box and the radiation was measured from a 30 cm distance from the centre of the box with a dosimeter. The required radioactivity was then transferred to the v-vial, and the shipping vial was measured again. After that, the v-vial was measured from the same distance from the centre of the box with dosimeter. RESULTS: Altogether 62 times the shipping vial with different activities were measured with a significant positive correlation between the amount of the activity measured in the iron chamber and the radiation dose, measured with dosimeter (r² = 0.98; p< 0.001). There was also a strong positive correlation between these measurements of the v-vial (r² = 0.98; p< 0.001). CONCLUSION: With measurement of the residual activity in the delivery box using a dosimeter the percentage of the whole injected activity can be easily calculated. This facilitates the calculation of the actual, achieved target and non-target dose in those cases, where therapy had to be stopped because of eminent flow reversal or obstruction.
Sujet(s)
Curiethérapie/méthodes , Emballage de médicament , Tumeurs du foie/radiothérapie , Radiométrie/méthodes , Dosimétrie en radiothérapie , Radio-isotopes de l'yttrium/analyse , Radio-isotopes de l'yttrium/usage thérapeutique , Absorption de rayonnement , Résines acryliques , Vecteurs de médicaments , Contamination de matériel , Humains , Microsphères , Lésions radiques/prévention et contrôle , Radioprotection/méthodes , Radiopharmaceutiques/analyse , Radiopharmaceutiques/usage thérapeutiqueRÉSUMÉ
UNLABELLED: [177Lu-DOTA0,Tyr3]-octreotate (177Lu-octreotate) in peptide receptor radionuclide therapy (PRRT) offers direct intra-therapeutic dosimetry. The aim of this study was to compare tumour and non-tumour parameters and assess intra-individual variations. PATIENTS, METHODS: Retrospective analysis of 53 consecutive PRRT treatment cycles (mean activity of 7.53 ± 0.46 GBq 177Lu-octreotate, intended four cycles at intervals of 10-14 weeks, standard nephroprotection) in 27 GEP NET patients. Extended planar dosimetry with serial whole-body imaging on selected, non-superimposed tumour and non-tumour regions; liver (LM), bone (BM), and other (OM) metastases. The per-cycle variation was compared with post-treatment response (CT/MRI three months post-treatment, modified SWOG criteria). RESULTS: Residence time in tumor lesions (133-147 h) exceeded that in kidneys (93 h). Tumour-to-kidney absorbed dose ratios ranged from 14 to 28 (LM, BM, OM). Intra-individual per-cycle dose variation was insignificant for kidneys, but significant for metastases (LM, BM, and OM; p < 0.05). The mean per-cycle decrease of tumour absorbed dose (ΔD/A0[%]) was linked to morphologic response after PRRT. A mean decrease of >20% was predictive of a partial or minor remission in all 11 evaluable patients, while absent significant dose reduction indicated stable or progressive disease in 4/5 patients. The dose decrease was unrelated to volume effects and also observed for BM. CONCLUSION: Besides confirmation of a favourable tumour-to-kidney parameter relation for 177Lu-octreotate, stepwise intra-lesional comparison seems to imply a prognostic impact of tumor dosimetry: The early per-cycle change ΔD/A0 between treatment cycles may predict the outcome after PRRT. Larger studies are needed to confirm this finding.
Sujet(s)
Tumeurs de l'appareil digestif/imagerie diagnostique , Tumeurs de l'appareil digestif/radiothérapie , Dépistage précoce du cancer/méthodes , Interprétation d'images assistée par ordinateur/méthodes , Octréotide/analogues et dérivés , Radiométrie/méthodes , Adulte , Sujet âgé , Relation dose-effet des rayonnements , Femelle , Humains , Mâle , Adulte d'âge moyen , Octréotide/usage thérapeutique , Pronostic , Scintigraphie , Radiopharmaceutiques/usage thérapeutique , Dosimétrie en radiothérapie , Reproductibilité des résultats , Sensibilité et spécificité , Résultat thérapeutiqueRÉSUMÉ
AIM: Peptide receptor radionuclide therapy with 177Lu-octreotate is an effective treatment option for metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET) and allows intratherapeutic imaging through a 177Lu-octreotate scan (LuS). The diagnostic value of this treatment scan is not yet established. This study aims to compare the sensitivity of LuS and bone scintigraphy (BS) regarding bone metastases and investigate potential implications of functional imaging results. PATIENTS, METHODS: We retrospectively analyzed 29 consecutive GEP NET patients with bone metastases and baseline BS treated with 177Lu-octreotate. A semi-quantitative scoring system was used for the comparative evaluation. Treatment outcome (time-to-progression of bone metastases) was correlated with the intra-individual imaging discrepancy (Kaplan-Meyer curves, log-rank test, p < 0.05). RESULTS: In 19 of 29 patients (65.5%) LuS was superior (LuS > BS), whereas in 10 patients (34.5%) both modalities were comparable. BS showed no additional (LuS-negative) metastatic bone lesions in our cohort. None of the investigated baseline characteristics was associated with imaging discrepancy. On the other hand, functional imaging discrepancy had no impact on treatment response (p = 0.43) or time-to-progression (p = 0.92). CONCLUSIONS: Intra-therapeutic 177Lu-octreotate imaging is superior over bone scintigraphy for detection of bone metastases in GEP NET. BS may help to distinguish osseous from non-osseous localization. The presence of an osteoblastic correlate in BS seems to have no impact on therapeutic outcome.
Sujet(s)
Tumeurs osseuses/imagerie diagnostique , Tumeurs osseuses/secondaire , Diphosphonates , Tumeurs gastro-intestinales/imagerie diagnostique , Tumeurs neuroendocrines/imagerie diagnostique , Tumeurs neuroendocrines/secondaire , Octréotide/analogues et dérivés , Composés organiques du technétium , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Tumeurs osseuses/radiothérapie , Femelle , Tumeurs gastro-intestinales/radiothérapie , Humains , Mâle , Adulte d'âge moyen , Tumeurs neuroendocrines/radiothérapie , Octréotide/usage thérapeutique , Pronostic , Scintigraphie/méthodes , Radiopharmaceutiques/usage thérapeutique , Reproductibilité des résultats , Études rétrospectives , Sensibilité et spécificité , Résultat thérapeutiqueSujet(s)
Prothèse valvulaire cardiaque/effets indésirables , Ostéoporose/diagnostic , Ostéoporose/étiologie , Tomographie par émission de positons/méthodes , Maladies du rachis/diagnostic , Maladies du rachis/étiologie , Tomodensitométrie/méthodes , Sujet âgé , Valve aortique/chirurgie , Fluorodésoxyglucose F18 , Humains , Mâle , Radiopharmaceutiques , Vertèbres thoraciques/imagerie diagnostiqueSujet(s)
Tumeurs gastro-intestinales/traitement médicamenteux , Tumeurs gastro-intestinales/chirurgie , Tumeurs neuroendocrines/traitement médicamenteux , Tumeurs neuroendocrines/chirurgie , Traitement médicamenteux adjuvant , Association thérapeutique , Tumeurs gastro-intestinales/anatomopathologie , Tumeurs gastro-intestinales/radiothérapie , Humains , Thérapie moléculaire ciblée/méthodes , Stadification tumorale , Tumeurs neuroendocrines/anatomopathologie , Tumeurs neuroendocrines/radiothérapie , Médecine de précision , Pronostic , Radiothérapie/méthodes , Radiothérapie adjuvante , Somatostatine/analogues et dérivésSujet(s)
Carcinome papillaire/imagerie diagnostique , Radio-isotopes de l'iode/usage thérapeutique , Technétium (99mTc) sestamibi , Tumeurs de la thyroïde/imagerie diagnostique , Carcinome papillaire/radiothérapie , Faux négatifs , Faux positifs , Femelle , Humains , Adulte d'âge moyen , Scintigraphie , Thyroglobuline/sang , Tumeurs de la thyroïde/radiothérapie , Résultat thérapeutiqueRÉSUMÉ
AIM: Dosimetry in (131)I-lipiodol therapy for hepatocellular carcinoma (HCC) in the hitherto largest existing patient cohort. PATIENTS, METHODS: 38 courses of intra-arterial (131)I-lipiodol therapy with a total activity up to 6.7 GBq were performed in 18 patients with HCC. Liver and tumour volume were measured by computed tomography (CT) and (131)I-activity by scintigraphy on day 3, 6, 14, 28 and 42 after injection. Lipiodol deposition in tumour nodules as shown by CT rendered definite attachment to scintigraphic data possible. The radiation dose in tumour nodules, liver and lungs was calculated according to the MIRD concept and the tumour dose related to pre-therapeutic tumour volume, response and survival. RESULTS: Mean tumour dose was 23.6 +/- 3.6 Gy (14.2 +/- 2.1 mGy/MBq) with maximal 162 Gy (90.1 mGy/MBq) after one and 274 Gy after three courses. The dose to nontumourous liver was 1.9 +/- 0.2 Gy (1.2 +/- 0.1 mGy/MBq) and the mean dose ratio of tumour / nontumourous liver 11.1 +/- 1.7 (max. 82). The pulmonary dose was 25.9 +/- 1.8 mGy (16.3 +/- 1.2 microGy/MBq) and therefore much lower. There was a reciprocal relation between tumour dose and pretherapeutic tumour volume. Tumour dose had no effect on response or survival. CONCLUSION: High radiation doses are particularly in small tumour nodes achievable but not necessarily related to tumour response. The dose of non-tumourous liver and lungs is much lower.